Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 18/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105455 | 0.84 | KMT2A (0.33) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL22105364 | 0.72 | TPH1 (0.51) | — | |
| SCHEMBL22105372 | 0.66 | ALDH1A1 (0.32) | PDE5A | |
| SCHEMBL22105458 | 0.63 | KDM4E (0.57) | — | |
| SCHEMBL22105713 | 0.63 | ALDH1A1 (0.50) | — | |
| SCHEMBL22105780 | 0.61 | ALDH1A1 (0.38) | — | |
| SCHEMBL21316270 | 0.60 | F11 (0.37) | PDE5A | |
| SCHEMBL22105567 | 0.58 | TSHR (0.45) | — | |
| SCHEMBL235974 | 0.57 | PDE5A (0.81) | PDE5APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7440296 | 0.57 | PDE5A (0.81) | PDE5APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-12-14 | — | — | US | disclosed |
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190093-A1 | SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | PDE5A 468/4885FKBP1A 1635/4885PDE4A 756/4885 |
| US-11198696-B2 | Substituted xanthines as inhibitors of transient receptor potential cation channel subfamily c, member 5 activity | TRPC5, TRPM5, TRPC4 | PDE5A 354/4885FKBP1A 2756/4885PDE4A 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.